PATENT CLAIM ANALYSIS

Application Number: 15766340
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "254100"]

Abstract:
Topical administration of VEGF inhibitors such as, without limitation, rifamycin compounds are useful for treating skin disorders such as treating and/or reducing scars such as hypertrophic scars, and useful for treating acne and underlying acne symptoms such as skin redness.

Claim (Index 5):
A method of reducing hypertrophic scar or a method of preventing scar formation comprising administering topically to a patient in need thereof a therapeutically effective amount of an inhibitor of a VEGF inhibitor, wherein the scar formation results at least in part from neovascularization.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 91.0
- Lexical Diversity: 1.57143
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12063300', '14376789', '13622120', '12936722', '13478982']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7489097719651496
- 35 USC 102 Novelty (BERT): 0.5006420250900595
- Combined Prediction Score: 0.7240829972776406
- Mean Citation Score: 203.846566
- Max Citation Score: 208.92108
- Similarity Product: 130.28323657382012

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test